Mizuho Lowers PT on Embecta Corp. (EMBC) to $13 From $15, Keeps a Neutral Rating

Embecta Corp. (NASDAQ:EMBC) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On May 23, Mizuho lowered the firm’s price target on Embecta Corp. (NASDAQ:EMBC) to $13 from $15, keeping a Neutral rating on the shares. The rating came after analyst day, with the firm telling investors in a research note that the company’s long-term guidance calls for sales to stay relatively flat through 2028.

Following similar circumstances, Travis Steed from Bank of America Securities maintained a Sell rating on Embecta Corp. (NASDAQ:EMBC) in a report released on May 28, setting a price target of $18.00.

Embecta Corp. (NASDAQ:EMBC) provides medical devices used to treat diabetes. The company’s offerings include syringes, pen needles, and safety devices fitted with a digital application.

While we acknowledge the potential of EMBC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.